Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery

Vox Sanguinis

Volumn 84, Issue 1, 2003, Pages 65-67

  Postma, M J ^a   Van de Watering, L M G ^b   De Vries, R ^a   Versmoren, D ^a   Van Hulst, M ^a,c   Tobi, H ^a   Van der Poel, C L ^d   Brand, A ^b  

^a GUIDE/GRIP   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE TRANSFUSION; HEART SURGERY; HUMAN; LEUKAPHERESIS; LEUKOCYTE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURGICAL PATIENT;

CARDIAC SURGICAL PROCEDURES; CELL SEPARATION; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; HUMANS; LEUKOCYTES; NETHERLANDS; POSTOPERATIVE COMPLICATIONS;

EID: 0038667472     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00245.x     Document Type: Article

References (13)

1. Van de Watering LMG, Hermans J, Houbiers JGA, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A: Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562-568
2. College voor Zorgverzekemars (CvZ): Richtlijnen voor Farmacoeconomisch Onderzoek (Guidelines for Pharmaco-Economic Research; in Dutch). Amstelveen: CvZ, 1999
3. Gold MR, Siegel JE, Russel LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
4. Briggs A, Fenn P: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7:723-740
5. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with mulitivessel disease. N Engl J Med 1996; 335:217-225
6. Oostenbrink JB, Koopmanschap MA, Rutten FFH: Handleiding voor Kostenonderzoek (Guidelines for Costing; in Dutch). Rotterdam: Institute for Medical Technology Assessment, 2000
7. Sanquin Blood Supply Foundation: Beleidsplan 2001 (Policy Plan; in Dutch). Amsterdam: Sanquin, 2000
8. Owens DK: Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13:716-717
9. Jensen LS, Grunnet N, Hanberg-Sørensen F, Jørgensen J: Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35:719-722
10. Hjelmgren J, Berggren F, Andersson F: Health economic guidelines: similarities, differences and some implications. Value Health 2001; 4:225-250
11. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing (CBO): Consensus Cholesterol (in Dutch). Utrecht: CBO, 1998
12. Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJW: Economic evaluation of influenza vaccination: assessment for the Netherlands. Pharmacoeconomics 1999; 16:33-40
13. Ruitenberg EJ, Houweling H: Universal vaccination against group-C Meningococci and Pneumococci: summary of the advice from the Health Council of the Netherlands. Ned Tijdschr Geneeskd 2002; 146:939-940